GlaxoSmithKline is buying Human Genome Sciences for $3.6 billion, giving it full ownership of Benlysta, along with albiglutide and darapladib, after months of M&A intrigue. “We are pleased to have ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Benlysta (belimumab) - Drug Insight and Market Forecast - 2030 ...

Please provide your email address to receive an email when new articles are posted on . Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic ...

Benlysta, GlaxoSmithKline's treatment for autoimmune disease lupus has been recommended by NICE, after the company agreed to a price cut and a real world data study. The decision comes after years of ...

People with lupus often need to use medicines to manage their symptoms. Although there are many oral medicines that treat lupus, some people with more severe symptoms may not get enough benefit from ...

Benlysta represents a breakthrough in the treatment of lupus. Benlysta is the first drug approved to treat lupus in more than 50 years AND is the first drug developed specifically for lupus since the ...